Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections.
Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections.
复制标题
人类单克隆抗体可在固定组织切片中区分皮肤恶性黑色素瘤和良性痣。
DOI：
10.1111/1523-1747.ep12284184
复制
发表时间：
1986
期刊：
影响因子：
--
通讯作者：
Kan-Mitchell,J
中科院分区：
文献类型：
--
作者：
Imam,A;Mitchell,MS;Modlin,RL;Taylor,CR;Kempf,RA;Kan-Mitchell,J
人单克隆抗体是通过将小鼠骨髓瘤细胞的非分泌变体与从转移性皮肤恶性黑色素瘤患者淋巴结获得的淋巴细胞融合而产生的。两种人IgG单克隆抗体，指定2-139-1和6-26-3，被广泛研究了其结合到64份福尔马林固定，石蜡包埋的组织切片标本中的细胞的模式。其中包括：皮肤黑色素瘤23例，眼黑色素瘤2例，恶性雀斑样痣4例，良性痣27例，皮肤基底细胞肿瘤2例，鳞状细胞肿瘤2例，正常皮肤4例。采用抗生物素蛋白-生物素-免疫过氧化物酶直接染色法。在这些条件下，抗体以可变强度与所有18个原发性皮肤恶性黑素瘤、5个转移性皮肤黑素瘤和两个眼部黑素瘤反应。抗体2-139-1与4份恶性雀斑样痣标本中的1份反应，6-26-3与4份恶性雀斑样痣标本中的3份反应。两个5发育不良痣反应与两种抗体，每一个细胞的比例小于黑色素瘤。与其他22个代表一系列组织学类型的痣或正常黑素细胞无反应。皮肤基底细胞癌和鳞状细胞癌也未染色。这些人单克隆抗体似乎可用于区分恶性黑色素瘤与良性痣（发育不良痣除外）以及常规制备的组织切片中的皮肤基底癌和鳞状癌。它们还可以帮助识别在人类中具有免疫原性的细胞质抗原。
Human monoclonal antibodies were generated by fusing a nonsecretory variant of murine mycloma cells with lymphocytes obtained from the lymph nodes of patients with metastatic cutaneous malignant melanoma. Two human IgG monoclonal antibodies, designated 2-139-1 and 6-26-3, were extensively studied for their patterns of binding to cells in 64 specimens of formalin-fixed, paraffin-embedded tissue sections. These comprised: (1) 23 cutaneous and 2 ocular melanomas; (2) 4 specimens of lentigo maligna; (3) 27 benign nevi; (4) 2 basal and 2 squamous cell neoplasms of the skin; and (5) 4 specimens of normal skin. A direct avidin-biotin-immunoperoxidase staining method was used. Under these conditions, the antibodies reacted with variable intensity to all 18 primary cutaneous malignant melanomas, 5 metastatic cutaneous melanomas, and both ocular melanomas. Antibody 2-139-1 reacted with 1 of 4 specimens and 6-26-3 with 3 of 4 specimens of lentigo maligna. Two of 5 dysplastic nevi reacted with both antibodies, each with a smaller proportion of cells than with melanomas. There was no reactivity with the 22 other nevi representing a spectrum of histologic types or with normal melanocytes. Basal cell and squamous cell carcinomas of the skin also were not stained. These human monoclonal antibodies appear to be useful in distinguishing malignant melanomas from benign nevi, with the exception of dysplastic nevi, and from basal and squamous cancers of the skin in routinely prepared tissue sections. They may also help to identify the cytoplasmic antigens that are immunogenic in humans.